Table 1. Patient characteristics.
| Characteristics | n = 28 |
|---|---|
| Sex | |
| Male/female | 18/10 |
| Median age at transplant, yr (range) | 16.3 (1.3–21.4) |
| Diagnoses, No. (%) | |
| Ewing sarcoma family | 11 (39.3) |
| Osteosarcoma | 6 (21.4) |
| Synovial sarcoma | 3 (10.7) |
| Desmoplastic small round cell tumor | 3 (10.7) |
| Rhabdomyosarcoma | 2 (7.1) |
| Others* | 3 (10.7) |
| Treatment prior to transplant, No. (%) | |
| Chemotherapy alone | 8 (28.6) |
| Chemotherapy + Surgery | 10 (35.7) |
| Chemotherapy + Radiotherapy | 6 (21.4) |
| Chemotherapy + Surgery + Radiotherapy | 4 (14.3) |
| Primary site of tumor, No. (%) | |
| Soft tissue origin | 20 (71.4) |
| Bone origin | 8 (28.6) |
| Cause of HDCT/auto-SCT, No. (%) | |
| High-risk tumor | 18 (64.3) |
| Recurrent tumor | 10 (35.7) |
| Tumor status prior to HDCT/auto-SCT, No. (%) | |
| Complete response | 15 (53.6) |
| Partial response | 5 (17.9) |
| Stable disease | 2 (7.1) |
| Progressive disease | 6 (21.4) |
HDCT/auto-SCT, high-dose chemotherapy and autologous stem cell transplantation.
*Others included malignant peripheral nerve sheath tumor (n = 1), epithelioid inflammatory myofibroblastic sarcoma (n = 1), and epithelioid sarcoma (n = 1).